Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

Main Article Content

April W Armstrong
Kim A Papp
Joe Zhuo
Brandon Becker
Yichen Zhong
Jennifer L Beaumont
Michael DeRosa
Renata M Kisa
Subhashis Banerjee
Bruce Strober

Keywords

deucravacitinib, psoriasis, clinical response, clinical outcomes, TYK2 inhibitor, POETYK

Abstract

N/A

References

1. Warren RB, et al. Ann Rheum Dis. 2022;81:1570-1571.

2. Papp KA, et al. [poster] Presented at the 30th Congress of the European Academy of Dermatology and Venereology (EADV); September 29–October 2, 2021; virtual meeting.

3. Augustin M, et al. [poster] Presented at the American Academy of Dermatology (AAD) Annual Meeting; March 25–29, 2022; Boston, MA.

4. Armstrong AW, et al. Am J Clin Dermatol. 2019;20:155-164.

5. Loft ND, et al. Acta Derm Venereol. 2019;99:1224-1230.

6. Schäfer I, et al. Eur J Dermatol. 2010;20:62-67.

7. Thaçi D, et al. Dermatol Ther (Heidelb). 2022;12:495-510.

8. Price A, Cohen DE. Dermatitis. 2014;225:334-344.

9. Armstrong AW, et al. J Dermatol Treat. 2019;30:27-34

Most read articles by the same author(s)

1 2 3 4 5 > >>